OTTO Life Science Engineering GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
OTTO Life Science Engineering GmbH - overview
Established
2017
Location
Nurnberg, -, Germany
Primary Industry
Business Support Services
About
Based in Germany, OTTO Life Science Engineering GmbH operates as a facility management company that offers engineering services. In July 2024, SPIE S. A. , a portfolio company of Bpifrance Investissement and Peugeot Invest, agreed to acquire an 87% majority stake in OTTO Life Science Engineering GmbH from Equistone Partners Europe.
The deal is expected to be completed in Q3 2024 and is subject to customary closing conditions, among which is German antitrust approval. Following the transaction, the current management team will retain a 13% minority stake in the company. As of 2024, the company is led by its CEO, Alf Kain. OTTO Life Science Engineering provides EPC services (engineering, procurement, and construction) for pharmaceutical and biotech production facilities and laboratories.
The company offers a comprehensive range of services for the life science industry, covering the entire project lifecycle. From initial concept and planning to construction, commissioning, qualification, validation, and ongoing facility management, the firm provides expert solutions. Their services include process engineering, architecture, technical building equipment, cleanroom construction, and more.
Current Investors
Equistone Partners Europe
Primary Industry
Business Support Services
Sub Industries
Consulting Services, Engineering, Construction
Website
www.otto-lse.com
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
OTTO Life Science Engineering GmbH - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - |
| EBITDA (USD) | - | - | 5,122,497.9 | - | - | - |
| Operating Income (USD) | - | - | 4,916,652.2 | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - |
| NET Income (USD) | 771,783.4 | 3,333,432 | 3,370,076.7 | - | - | - |
| % Net Margin | - | - | - | - | - | - |
OTTO Life Science Engineering GmbH - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | OTTO Life Science Engineering GmbH | - | ||||||||
| Buyout | Completed | OTTO Life Science Engineering GmbH | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.